Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 7:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vogelxo Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone (HOP 5) Testicular Aspiration Addendum

NCT00156650
View directory record Official record
Conditions
Contraception
Interventions
Acyline, Testosterone Gel, Depo-Medroxyprogesterone
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 18, 2008 · Synced Sep 25, 2026, 7:30 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue

NCT00490555
View directory record Official record
Conditions
Healthy
Interventions
Testosterone gel, Dutasteride, Depo-Medroxyprogesterone (DMPA), Placebo Testosterone gel, Placebo dutasteride, Placebo DMPA
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Sep 25, 2026, 7:30 PM EDT
Completed Phase 4 Interventional Results available

Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy

NCT01201863
View directory record Official record
Conditions
Endocrine Dysfunction, Trauma, Brain Injury
Interventions
Androgel (Testosterone Gel), Placebo gel
Drug · Other
Lead sponsor
Craig Hospital
Other
Eligibility
16 Years to 65 Years · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Sep 25, 2026, 7:30 PM EDT
Recruiting Phase 2 Interventional

The COSMYC Trial (COmbined Suppression of MYC)

NCT06922318
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 25, 2026, 7:30 PM EDT
Completed Phase 2 Interventional

Testosterone Replacement to Alleviate Pain in Postmenopausal Women (TRAPP Trial)

NCT04895306
View directory record Official record
Conditions
Pain, Opioid Use, Androgen Deficiency, Back Pain
Interventions
Testosterone Cypionate, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 25, 2026, 7:30 PM EDT
Completed Phase 4 Interventional

TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY

NCT03325647
View directory record Official record
Conditions
Klinefelter Syndrome
Interventions
Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution, Placebo injectable saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
31 Days to 90 Days · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Sep 25, 2026, 7:30 PM EDT
Completed Phase 3 Interventional

Low-Dose Testosterone in Improving Libido in Postmenopausal Female Cancer Survivors

NCT00075855
View directory record Official record
Conditions
Cancer Survivor, Sexual Dysfunction, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
therapeutic testosterone, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
16
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Urbana, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 25, 2026, 7:30 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

An Open-Label Study of 50 Mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low Testosterone and HSDD

NCT06082817
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Oral Testosterone Undecanoate
Drug
Lead sponsor
San Diego Sexual Medicine
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Sep 25, 2026, 7:30 PM EDT
Recruiting Phase 4 Interventional

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

NCT06733350
View directory record Official record
Conditions
Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Biopsy of Prostate, Biospecimen Collection, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Therapeutic Testosterone
Procedure · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 25, 2026, 7:30 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Androgen Effects on the Reproductive Neuroendocrine Axis, 2025 Version

NCT07092527
View directory record Official record
Conditions
Transgenderism, Reproductive Issues
Interventions
Testosterone Cypionate 50 milligrams per millileter (mg/mL) Injectable Solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 25, 2026, 7:30 PM EDT
Completed Phase 2 Interventional Results available

Testosterone and Growth Hormone for Bone Loss in Men

NCT00080483
View directory record Official record
Conditions
Hypopituitarism, Hypogonadism, Growth Hormone Deficiency
Interventions
Testosterone plus somatropin, testosterone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Sep 25, 2026, 7:30 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

ITT4 Intratesticular Hormonal Milieu in Man (ITT4)

NCT01215292
View directory record Official record
Conditions
Healthy Males
Interventions
Acyline, Testosterone gel, ketoconazole 400, Ketoconazole 800, Dutasteride, Anastrozole, Placebo ketoconazole
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 30, 2014 · Synced Sep 25, 2026, 7:30 PM EDT
Completed Phase 2 Interventional Results available

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

NCT03516812
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment, Survey Administration, Testosterone Enanthate, Testosterone Cypionate
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 25, 2026, 7:30 PM EDT
Recruiting Phase 2 Interventional

Testosterone Treatment in Men With Chronic Kidney Disease

NCT05249634
View directory record Official record
Conditions
Hypogonadism, Male, Kidney Disease, Chronic
Interventions
Jatenzo Pill
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 25, 2026, 7:30 PM EDT
Completed Phase 2 Interventional Results available

The Effect on Androxal Versus Androgel on Morning Testosterone in Men With Secondary Hypogonadism (Low Testosterone)

NCT01386606
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal (enclomiphene citrate), Testosterone
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Sep 25, 2026, 7:30 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Natesto Testosterone Nasal Gel for Hypogonadal Men

NCT05484167
View directory record Official record
Conditions
Erectile Dysfunction, Sexual Dysfunction
Interventions
Natesto Nasal Product, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 64 Years · Male only
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 25, 2026, 7:30 PM EDT
Recruiting Phase 2 Interventional

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

NCT07142551
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue, Darolutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 25, 2026, 7:30 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®

NCT01096329
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
45 Years to 65 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 25, 2026, 7:30 PM EDT
Completed Phase 2 Interventional Results available

Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism

NCT02777242
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone enanthate auto-injector
Combination Product
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Birmingham, Alabama • New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 25, 2026, 7:30 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations

NCT00857454
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone MD-Lotion
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
11
States / cities
Birmingham, Alabama • Tuscon, Arizona • Burbank, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2011 · Synced Sep 25, 2026, 7:30 PM EDT
Completed Phase 3 Interventional Results available

A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy

NCT01816295
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone Solution, Placebo Solution
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
45
States / cities
Homewood, Alabama • Chandler, Arizona • Glendale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2015 · Synced Sep 25, 2026, 7:30 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

The Effect of 5-Alpha Reductase on Testosterone in Men

NCT00070733
View directory record Official record
Conditions
Sex Disorders
Interventions
testosterone enanthate, duastride
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
21 Years to 40 Years · Male only
Enrollment
184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2005 · Synced Sep 25, 2026, 7:30 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

NCT00467987
View directory record Official record
Conditions
Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism
Interventions
androgel, placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
31 Years to 60 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 25, 2026, 7:30 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate

NCT01327495
View directory record Official record
Conditions
Healthy
Interventions
placebo acyline, placebo gel, Testosterone 1% gel 1.25 g, Testosterone 1% gel 2.5 g, Testosterone 1% gel 5.0 g, testosterone 1% gel 10 g, testosterone 1% gel 15 g, Acyline
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 25, 2026, 7:30 PM EDT